#USA #Washington #Cirius Therapeutics #cardiometabolic #CIR-0602K

Cirius Therapeutics Showcases Cardiometabolic Advances

Cirius Therapeutics, Inc., known for developing groundbreaking therapies for insulin resistance and metabolic disorders, recently announced significant findings regarding their clinical candidate, CIR-0602K. At the upcoming Global Cardiovascular Clinical Trialists (CVCT) Forum 2025, scheduled for December 8-10 in Washington, DC, CEO Robert Beardsley, PhD, will present a collection of compelling data that underlines the potential of CIR-0602K to enhance cardiometabolic health.

Insights from Phase 2 Trials

The presentation, titled "Incretin-Based Weight Management Medicines - Weight Loss and Muscle Health Hype or Hope," will delve into results from earlier Phase 2 trials. These trials emphasize CIR-0602K's unique mechanism of addressing vital cardiovascular health factors effectively. The data highlights several improvements:

Metabolic Control and Glycemic Stability

• - HbA1c Reduction: The findings indicate a reduction in HbA1c levels ranging from 0.5% to 1.3% in participants not meeting their glucose targets. Elevated HbA1c levels are strongly correlated with increased risk for micro and macrovascular diseases and cardiovascular incidents.
• - Insulin Resistance Improvements: Participants displayed significant decreases in insulin resistance and fasting insulin levels, diminishing by up to 50%. Chronic elevated insulin levels are linked to ischemic heart disease and major adverse cardiovascular events (MACE).
• - Efficacy with Concurrent GLP-1 Therapy: Even patients already on stable GLP-1 therapy experienced these favorable outcomes when treated with CIR-0602K.

Inflammatory Markers

• - Decreased High-Sensitivity C-Reactive Protein (hsCRP): Participants with baseline hsCRP over 3 mg/L experienced a notable dip of approximately 40%. Elevated hsCRP levels indicate heightened future cardiovascular risk.

Cardiovascular Health Indicators

• - Improvements in Lipid Profile: Participants saw increased levels of HDL cholesterol, a beneficial shift in lipoprotein subclasses, and reductions in blood pressure and endothelin levels.
• - Body Composition Enhancements: Moreover, the treatment led to an increase in lean body mass and strength, helping mitigate the muscle loss associated with conventional weight loss therapies.

The favorable reprogramming of white adipose tissue (WAT) was also reported, marking a transition from pro-inflammatory states to anti-inflammatory characteristics, and fostering increased metabolic activity. This biological transformation was previously documented in animal models, showcasing CIR-0602K’s ability to enhance muscle preservation and metabolic function.

Future Directions

Dr. Beardsley remarked, "These comprehensive data pieces present a potent narrative regarding the prospective influence of CIR-0602K on cardiovascular outcomes. Cardiometabolic health initiates within each cell's mitochondria. By targeting and reprogramming mitochondrial dysfunction, CIR-0602K offers a forward-thinking solution for individuals grappling with cardiovascular disease threats."

The data shared will not only outline cardiometabolic benefits but will also touch upon cardiovascular endpoints from recently completed trials in Type 1 diabetes. Cirius Therapeutics remains committed to advancing patient health, and their upcoming presentation promises to shed light on innovative measures that could redefine treatment paradigms in cardiometabolic diseases.

In conjunction with the presentation, Dr. Beardsley will partake in a panel discussion titled "Industry Perspectives on Muscle Sparing/Building Agents During Weight Loss: A 'Need' or a 'Want?'"

The CVCT Forum is set to serve as a platform for cutting-edge developments in cardiovascular clinical research, and Cirius Therapeutics’ promising candidate CIR-0602K is positioned to be a focal point of discussion, with expectations to influence future therapies in the realm of cardiometabolic health.

For more information about Cirius Therapeutics and their innovative therapies, visit www.CiriusTx.com.